ABVX:NASDAQ
Abivax SA
117,13 US$
arrow_downward
-0,41%(-0,48) 1K
122,16 US$
arrow_upward
+4,29% (+5,03)todayBirjadan oldin
Savdolar yopilgan: 4-may, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoABVX tikeri uchun statistika yaratilmoqda...
Ochish
118,31 US$
Yuqori
119,04 US$
Past
114,85 US$
Bozor kapitali
8,33 mlrd
Oʻrtacha hajm
969,53 ming
Hajmi
25,16 ming
52 haftalik eng yuqori
148,83 US$
52 haftalik eng past
5,59 US$
Muomaladagi aksiyalar
79,29 mln
Xodimlar soni
69
Yangiliklar
Internetdagi manbalardan
TradingView
·
3 soat oldin
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Idéal Investisseur
·
23 soat oldin
Abivax Shares Climb 5.55% in Chicago During Digestive Disease Week
MarketBeat
·
2 kun oldin
Pictet Asset Management Holding SA Sells 72,387 Shares of Abivax SA Sponsored ADR $ABVX
Newser
·
2 hafta oldin
Abivax (ABVX) Stock Closes Position (-2.86%) 2026-04-20 - Continuation Pattern
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni69
Asos solingan4-dek, 2013
Bosh ofislar-
Sektor-
Veb-saytabivax.com
AI kontentda xatolar boʻlishi mumkin. Batafsil